Amgen, Inc.

{
  "main_header": {
    "sid": 1150325,
    "name": "Amgen, Inc.",
    "stock_name": "Amgen, Inc.",
    "full_name": "Amgen, Inc.",
    "name_url": "stocks-analysis/amgen-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "344.75",
    "chg": 54.77,
    "chgp": "18.89%",
    "dir": 1,
    "prev_price": "289.98",
    "mcapval": "185,021.96",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US0311621009",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "1.94 M",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/amgen-inc-1150325-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Amgen, Inc. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amgens-valuation-grade-downgraded-from-attractive-to-fair-amid-price-fluctuations-3667012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AmgenInc_valuationdot_3667012.png",
        "date": "2025-11-03 15:28:03",
        "description": "Amgen, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 22 and a Price to Book Value of 25.15. The company demonstrates strong financial health, evidenced by a high ROE of 116.13% and a PEG ratio of 0.27, amidst a competitive pharmaceutical landscape."
      },
      {
        "title": "Amgen, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amgen-inc-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3651977",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AmgenInc_technicaldot_3651977.png",
        "date": "2025-10-28 15:05:28",
        "description": "Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance."
      },
      {
        "title": "Is Amgen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amgen-inc-technically-bullish-or-bearish-3651246",
        "imagepath": "",
        "date": "2025-10-28 11:38:36",
        "description": "As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The MACD shows a conflicting mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Dow Theory indicates a mildly bullish stance on the weekly timeframe but is also mildly bearish monthly. \n\nIn terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, with a year-to-date return of 11.94% compared to the S&P 500's 15.47%, and a one-year return of -7.58% versus the S&P 500's 16.90%. Overall, the mixed signals suggest caution in the current market environment...."
      }
    ],
    "total": 21,
    "sid": "1150325",
    "stock_news_url": "https://www.marketsmojo.com/news/amgen-inc-1150325"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Amgen, Inc. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape

2025-11-03 15:28:03

Amgen, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 22 and a Price to Book Value of 25.15. The company demonstrates strong financial health, evidenced by a high ROE of 116.13% and a PEG ratio of 0.27, amidst a competitive pharmaceutical landscape.

Read full news article

Amgen, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-28 15:05:28

Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance.

Read full news article

Is Amgen, Inc. technically bullish or bearish?

2025-10-28 11:38:36

As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The MACD shows a conflicting mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Dow Theory indicates a mildly bullish stance on the weekly timeframe but is also mildly bearish monthly. In terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, with a year-to-date return of 11.94% compared to the S&P 500's 15.47%, and a one-year return of -7.58% versus the S&P 500's 16.90%. Overall, the mixed signals suggest caution in the current market environment....

Read full news article

View All News